Lopinavir/ritonavir in the treatment of HIV-1 infection: a review
Open Access
- 1 October 2008
- journal article
- review article
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. ume 4 (5) , 1023-1033
- https://doi.org/10.2147/tcrm.s3285
Abstract
Lopinavir/ritonavir in the treatment of HIV-1 infection: a review Ashish Chandwani1, Jonathan Shuter21Division of Infectious Diseases, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, NY, USA; 2AIDS Center and Division of Infectious Diseases, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, NY, USA Lopinavir/ritonavir is the first and only coformulated HIV-1 protease inhibitor (PI). Large clinical trials have demonstrated lopinavir/ritonavirâ??s clinical efficacy in both antiretroviral-naïve and -experienced patients. The immunologic and virologic benefits of treatment with this agent have been proven in HIV-infected adults, adolescents, and children. Smaller studies support the use of lopinavir/ritonavir monotherapy as a therapeutic option in certain patients. The drug is characterized by a high genetic barrier to resistance, and appears to be more forgiving of non-adherence than earlier, unboosted PIs. The most frequent side effects observed are diarrhea, nausea, and vomiting. These gastrointestinal adverse effects are generally mild to moderate. Metabolic derangements, including hyperlipidemia and glucose intolerance, have also been observed in lopinavir/ritonavir recipients. As the menu of available antiretroviral agents continues to expand, lopinavir/ritonavir remains a proven and effective drug for the treatment of HIV infection.Keywords: lopinavir/ritonavir, protease inhibitor, HIV, antiretroviral, Kaletra®Keywords
This publication has 55 references indexed in Scilit:
- Improving lopinavir genotype algorithm through phenotype correlationsAIDS, 2003
- Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected childrenThe Pediatric Infectious Disease Journal, 2003
- Genotypic and Phenotypic Cross-Resistance Patterns to Lopinavir and Amprenavir in Protease Inhibitor-Experienced Patients with HIV ViremiaAIDS Research and Human Retroviruses, 2002
- Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV InfectionNew England Journal of Medicine, 2002
- Analysis of the Virological Response with Respect to Baseline Viral Phenotype and Genotype in Protease Inhibitor-Experienced HIV-1-Infected Patients Receiving Lopinavir/Ritonavir TherapyAntiviral Therapy, 2002
- Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease Inhibitor-Experienced PatientsJournal of Virology, 2001
- ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week resultsAIDS, 2001
- Randomized Study of Saquinavir with Ritonavir or Nelfinavir Together with Delavirdine, Adefovir, or Both in Human Immunodeficiency Virus–Infected Adults with Virologic Failure on Indinavir: AIDS Clinical Trials Group Study 359The Journal of Infectious Diseases, 2000
- Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV InfectionAnnals of Internal Medicine, 2000
- Potent Inhibition of the Cytochrome P-450 3A-Mediated Human Liver Microsomal Metabolism of a Novel HIV Protease Inhibitor by Ritonavir: A Positive Drug-Drug InteractionDrug Metabolism and Disposition, 1999